WGBS for Epigenetic Editing Safety Assessment
WGBS for Epigenetic Editing Safety Assessment
1. Background
1.1 Core Positioning
WGBS (Whole Genome Bisulfite Sequencing), with its unique technical advantages of single-base resolution and whole-genome coverage, provides regulatory-compliant safety assessment for epigenetic editing products. It is applicable to comprehensive off-target methylation detection for targeted methylation editing therapies including CRISPRoff, dCas9-DNMT3A, dCas9-TET1, and KRAB fusion systems.
1.2 Introduction to Epigenetic Editing Therapies
Epigenome editing is an emerging class of therapeutic strategies that modulate gene expression by targeted modification of DNA methylation or histone modification states at specific genomic loci. It achieves durable gene silencing or activation without altering the DNA sequence.
Mainstream Epigenetic Editing Systems
Editing System | Composition | Functional Mechanism | Clinical Application Direction |
|---|---|---|---|
CRISPRoff | dCas9-KRAB-DNMT3A-DNMT3L | Simultaneously establishes DNA methylation and H3K9me3 to achieve heritable gene silencing | Neurodegenerative diseases, metabolic disorders |
dCas9-DNMT3A | dCas9 fused to DNMT3A catalytic domain | De novo methylation at targeted sites | Tumor suppressor gene activation in cancer |
dCas9-TET1 | dCas9 fused to TET1 catalytic domain | Targeted demethylation (5mC → 5hmC → C) | Reactivation of tumor suppressor genes |
EvoETR | ZF/TALE-DNMT3A-3L | Evolutionarily optimized transcriptional repressor | PCSK9 silencing (lipid-lowering therapy) |
1.3 Clinical Translation Progress of Epigenetic Editing Therapies
(1) PCSK9 silencing: An in vivo study reported in 2024 demonstrated that a single administration achieved durable silencing of the PCSK9 gene in mouse liver, significantly reducing LDL cholesterol levels.
(2) Prion gene silencing: A ZF-DNMT3A system achieved durable silencing of the prion gene in mouse brain, providing a novel strategy for neurodegenerative diseases.
(3) Alzheimer's disease APP gene editing: dCas9-DNMT3A targeted methylation of the APP promoter reduced Aβ peptide production and improved cognitive function.
2. WGBS Detection Principle
2.1 Why WGBS Testing Is Essential
Regardless of the DNA-binding platform employed (ZF, TALE, or dCas9), all DNMT3A-based epigenetic editing systems share an inherent issue: the methyltransferase effector domain exhibits non-specific methylation activity independent of the targeting system when highly expressed, potentially inducing off-target methylation across the genome. Scientific rationale:
(1) The DNMT3A active site must recognize CG dinucleotide sequences to complete methyl transfer; therefore, DNMT3A may bind to any CG site in the genome.
(2) Multiple studies consistently demonstrate that even optimized engineered variants (such as the Q147L mutant of M.SssI) cannot fully eliminate non-specific activity.
(3) The failure of low-coverage methods such as RRBS to detect off-target effects does not equate to their absence.
(4) Only deep whole-genome methylation sequencing can reveal the true extent of non-specific methylation.
WGBS is the only technology capable of comprehensively assessing off-target methylation:
Detection Method | Coverage | Discovery Capability | Applicability |
|---|---|---|---|
WGBS | >90% CpG sites | ✓ Can detect unpredicted off-target sites | Gold standard for epigenetic editing products |
RRBS | 5–10% CpG sites | Limited, covers only CpG-enriched regions | Preliminary screening |
Methylation array | 2–3% preset sites | ✗ Cannot identify novel sites | Not applicable |
2.2 WGBS Technical Advantages
Why is WGBS the gold standard for safety assessment of epigenetic editing products?
Technical Parameter | WGBS | RRBS | Methylation Array | Advantage |
|---|---|---|---|---|
CpG Coverage | >90% (~28 million sites) | 5–10% | 2–3% | Comprehensive detection of unknown risks |
Resolution | Single-base | Single-base | Probe sites | Precise boundary localization |
Novel Discovery | ✓ | Limited | ✗ | Essential for off-target detection |
Enhancer/regulatory region coverage | ✓ Comprehensive | Biased toward CpG-dense regions | Preset probes | Epigenetic editing often targets enhancers |
Key Conclusion:
For epigenetic editing products: Only WGBS can comprehensively detect the genome-wide non-specific activity of methyltransferases such as DNMT3A — this constitutes the critical safety assessment data required by regulatory agencies.
2.3 WGBS Technical Principle
The core of WGBS is the use of bisulfite chemical conversion to achieve single-base discrimination between methylated and unmethylated cytosines. Combined with high-throughput sequencing and bioinformatic analysis, it constructs a genome-wide single-base resolution DNA methylation profile. The overall principle encompasses the following key steps: sample pre-processing, DNA extraction and library construction, bisulfite chemical conversion, high-throughput sequencing, and bioinformatic analysis with methylation identification.
Figure 1. Schematic diagram of the WGBS detection principle
3. Technology Innovation and Advantages
3.1 Optimized Library Construction and Sequencing Strategy
Technical Optimization for Epigenetic Editing Samples
Technical Step | Optimization Strategy | Advantage |
|---|---|---|
DNA extraction | Optimized for different cell types (neurons, hepatocytes, immune cells, etc.) | Maximizes high-quality DNA yield |
Fragmentation | Covaris sonication with precise control (200–300 bp peak) | Ensures fragment uniformity, improves coverage homogeneity |
Adapter ligation | Pre-methylated adapters | Prevents adapter loss during bisulfite conversion |
Bisulfite conversion | Optimized temperature, time, and reagent concentration | >99.5% conversion efficiency |
Amplification strategy | Low-cycle high-fidelity PCR | Reduces amplification bias, ensures quantitative accuracy |
Sequencing Depth Selection Guide
Application Scenario | Recommended Depth | CpG Coverage | Data Volume (Human Genome) |
|---|---|---|---|
Comprehensive IND/BLA submission-grade assessment | 30–40X | >90% | 120–160 GB |
Preclinical safety evaluation | 30X | >85% | 100–120 GB |
Product optimization and screening | 20–30X | >80% | 80–100 GB |
Preliminary off-target assessment | 15–20X | >75% | 60–80 GB |
3.2 Professional Bioinformatics Analysis Pipeline
Standard Analysis Modules
Module | Analysis Content | Output |
|---|---|---|
Data QC | Sequencing quality, conversion efficiency, coverage depth, duplication rate | QC report |
Alignment & Quantification | Bismark alignment, CpG/CHG/CHH methylation quantification | Methylation matrix |
Global Analysis | Chromosomal distribution, functional element classification statistics | Global methylation profile |
DMR Analysis | Differentially methylated region identification, statistical testing, effect size evaluation | DMR list and annotation |
Functional Annotation | Gene, enhancer, CpG island annotation | Functional annotation report |
Epigenetic Editing Product-Dedicated Analysis
Dedicated Module | Analysis Content |
|---|---|
On-target editing efficiency analysis | Methylation quantification at target sites, editing window profiling |
Genome-wide off-target screening | Unbiased DMR discovery, functional region enrichment analysis |
sgRNA off-target site verification | Methylation status check at predicted off-target sites |
Editing persistence tracking | Multi-timepoint methylation dynamic analysis |
4. Application Scenarios and Testing Plans
4.1 Detection Design Principles
Safety assessment of epigenetic editing products must address the following core questions:
(1) On-target editing efficiency: Has methylation at the target gene promoter/enhancer region been successfully established or removed?
(2) Editing specificity: Are there any unintended methylation changes across the genome?
(3) Editing persistence: Is the methylation state stably inherited through cell division?
(4) Functional relevance: Do the methylation changes affect the expression of critical genes?
4.2 In Vitro Epigenetic Editing Cell Product Assessment Plan
Sample Group | Sample Description | Sequencing Depth | Detection Purpose |
|---|---|---|---|
Unedited control cells | Untreated cells of identical origin and culture conditions | 30X | Establish methylation baseline |
Mock transfection control | Transfected with empty vector or non-targeting sgRNA only | 30X | Distinguish transfection-related vs. editing-specific effects |
Post-editing samples (early) | Collected 3–7 days post-editing | 30–40X | Assess immediate editing efficiency and off-target effects |
Post-editing samples (mid-term) | 2–4 weeks post-editing, after multiple cell divisions | 30X | Assess methylation maintenance stability |
Post-editing samples (long-term) | 8–12 weeks post-editing (if applicable) | 20–30X | Assess long-term stability |
4.3 In Vivo Epigenetic Editing Product Assessment Plan
Sample Group | Sample Description | Sequencing Depth | Detection Purpose |
|---|---|---|---|
Untreated control animals | Target organs from untreated animals of identical strain and age | 30X | Establish in vivo methylation baseline |
Vector control group | Animals receiving empty vector AAV/LNP only | 30X | Distinguish vector-related vs. editing-specific effects |
Edited group – target organ | Target organ (e.g., liver, brain) 1–2 weeks post-dosing | 30–40X | Assess editing efficiency and off-target effects in target organ |
Edited group – off-target organs | Non-target organs with potential vector biodistribution | 20–30X | Assess safety in off-target organs |
Long-term follow-up samples | Target organ 3–6 months post-dosing | 30X | Assess long-term in vivo stability |
4.4 Core Analysis Content
4.4.1 On-Target Editing Efficiency Assessment
(1) Single CpG site methylation levels at the target gene promoter/enhancer region
(2) Spatial distribution of methylation changes (editing window width)
(3) Consistency with the expected editing pattern (methylation vs. demethylation)
4.4.2 Genome-Wide Off-Target Methylation Screening
(1) Unbiased identification of differentially methylated regions (DMRs)
(2) Genomic distribution of DMRs (promoters, enhancers, gene bodies, intergenic regions)
(3) Functional enrichment analysis of DMR-associated genes
(4) DMR assessment for key safety-relevant pathways (tumor suppression, DNA repair, cell cycle)
4.4.3 Editing Persistence Tracking
(1) Dynamic methylation changes across different time points and passage numbers
(2) Methylation maintenance rate following cell division
(3) Methylation stability during differentiation/dedifferentiation processes
4.4.4 Functional Association Analysis (Can Be Combined with Transcriptomic Data)
(1) Correlation between methylation changes and gene expression alterations
(2) Pathway enrichment analysis of differentially methylated genes
(3) Key safety-relevant pathways (cell cycle, apoptosis, DNA repair, etc.)
5. Regulatory Support
5.1 FDA Regulatory Requirements
Although the 2024 FDA guidance "Human Gene Therapy Products Incorporating Human Genome Editing" is primarily directed at genome editing, its core principles are equally applicable to epigenetic editing products:
(1) Comprehensive product characterization: Detailed data on editing efficiency, specificity, and durability are required.
(2) Non-clinical safety studies: Off-target effects and their potential functional consequences must be assessed.
(3) Long-term follow-up plan: Attention to potential delayed-onset effects.
Special Considerations for Epigenetic Editing Products
Assessment Dimension | Specific Requirement | Value of WGBS |
|---|---|---|
Off-target methylation | Assess unintended genome-wide methylation changes | WGBS is the only technology for comprehensive detection |
Editing persistence | Verify whether the methylation state is stably heritable | Multi-timepoint WGBS to track methylation dynamics |
Reversibility | Assess whether the editing can be reversed (e.g., using CRISPRon) | WGBS to verify demethylation efficiency |
Tissue specificity | Differences in editing efficiency across tissues/cell types | Multi-tissue WGBS comparative analysis |
5.2 Regulatory Submission Support
Data Package Meeting IND/BLA Submission Requirements
Component | Content Description | Format |
|---|---|---|
Technical report | Methodology description, method validation, QC standards | PDF/Word |
Analysis report | Comprehensive analysis results, data interpretation, safety assessment conclusion | PDF/Word |
Raw data | FASTQ files, alignment files | Electronic data package |
Processed data | Methylation matrix, DMR list, annotation files | Electronic data package |
Professional Technical Support Services
(1) Project design consultation: Design optimal testing plans based on product type and regulatory requirements
(2) Sample strategy recommendations: Scientific design of sample types, quantities, and time points
(3) Data interpretation support: Assist in interpreting the biological and regulatory significance of analysis results
(4) Regulatory inquiry support: Assist in preparing responses to technical inquiries from regulatory agencies
(5) Multi-omics integration: Can be combined with RNA-seq, ATAC-seq, ChIP-seq, and other data for integrated analysis
6. Sample Requirements
DNA Sample Standards
Parameter | Standard Requirement | IND/BLA Submission Grade | Notes |
|---|---|---|---|
Total DNA amount | ≥3 μg | ≥5 μg | Higher depth sequencing requires more |
DNA concentration | ≥50 ng/μL | ≥100 ng/μL | — |
Purity (OD260/280) | 1.8–2.0 | 1.8–2.0 | Protein contamination affects conversion |
Integrity | Main band >10 kb | Main band >15 kb | Degradation affects data quality |
Cell / Tissue Samples (DNA Extraction Service Available)
Sample Type | Recommended Amount | Notes |
|---|---|---|
Edited cells | ≥5×10⁶ cells | Ensure cell viability and purity |
Primary cells | ≥1×10⁷ cells | Minimize culture time |
Tissue samples | ≥100 mg | Stored at −80°C, avoid repeated freeze-thaw cycles |
① All samples must meet the above quality standards to ensure accuracy and reliability of test results. ② For special sample types, please contact the GeneRulor technical team in advance (Tel: 400-6309596; Product ordering/technical support: service@generulor.com).
References
1. Nuñez JK, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184(9):2503-2519.
2. Cappelluti MA, et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature. 2024;627(8003):416-423.
3. Stepper P, et al. Efficient targeted DNA methylation with chimeric dCas9-Dnmt3a-Dnmt3L methyltransferase. Nucleic Acids Res. 2017;45(4):1703-1713.
4. Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462(7271):315-322.
5. FDA. Human Gene Therapy Products Incorporating Human Genome Editing. Guidance for Industry. January 2024.
![Micromessenger Scan to consult](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/2/ABUIABACGAAg9by4zQYo7oak_wUwxwY40QY.jpg",this,{"tips":"请使用微信扫一扫"});){kind=link}
![Linkedin LIN HUABING](javascript:Site.hoverQrCode("//33974620.s21i.faiusr.com/4/ABUIABAEGAAgloWpzgYo0eeGgAUwhgQ4igQ.png",this,{"tips":"Scan QR code"});){kind=link}